NetScientific PLC Vortex Biosciences Appoints Non-Executive Director
26 Outubro 2016 - 9:30AM
RNS Non-Regulatory
TIDMNSCI
NetScientific PLC
26 October 2016
("NetScientific" or the "Company" or the "Group")
Portfolio Company Vortex Biosciences Appoints Deborah Neff ex
Chief Operating Officer of Complete Genomics Inc as Non-Executive
Director
London, UK - October 26 - NetScientific plc ("NetScientific",
AIM:NSCI), the transatlantic healthcare IP commercialisation group,
announces that its portfolio company, Vortex Biosciences, has
appointed Deborah Neff as a Non-Executive Director to its Board of
Directors, effective immediately. Deborah has served in a number of
senior positions in healthcare companies, including a 15-year
career at Becton Dickinson & Co in executive management
positions.
Commenting on the appointment, NetScientific's Chief Executive
Officer and Chairman of Vortex, Francois R. Martelet, said: "We are
delighted to welcome Deborah to the Vortex team. She will play a
critical role providing strategic oversight, as the Company's
circulating tumor cell enrichment system, the VTX-1, is progressing
towards commercialisation."
Vortex Bioscience's press release follows:
Vortex Biosciences Appoints Non-Executive Director
Deborah J. Neff Brings Extensive Strategic Leadership to Vortex
Board of Directors
MENLO PARK, CA, October 25, 2016 - Vortex Biosciences, provider
of circulating tumor cell (CTC) capture systems, is pleased to
announce that Deborah J. Neff has accepted the role as
Non-Executive Director. Deborah has served in a number of
leadership positions in healthcare companies, including a 15-year
career at Becton Dickinson & Co in executive management
positions, making her ideally positioned to provide oversight to
Vortex Biosciences as it approaches commercialization of its first
product, the VTX-1 Liquid Biopsy System.
During her time at Becton Dickinson & Co, she was the
Worldwide President of BD Biosciences with global P&L
responsibilities. Under her leadership, the BD Biosciences grew to
be a $700M business. Most recently, Deborah was the Chief Operating
Officer of Complete Genomics Inc., where she led strategy
development, established and delivered financial and operational
milestones, and was responsible for operations, commercial and
product development. Prior to that she was the President and Chief
Executive Officer at both Predicant Biosciences Inc, and at
Pathwork Diagnostics Inc., where she led the raising of capital,
hiring of the executive team, development of an FDA cleared
product, and achieved multi-million dollar annual sales. She was a
member of the Board of Directors at Advanced Medical Optics Inc.
and ForteBio Corporation Inc. prior to their being acquired, and is
currently a member of the Board of Directors at Bio-Rad
Laboratories. Her experience in leading both large and small
companies in the development and execution of a strategic vision
will be a tremendous asset to Vortex.
"Deborah will be a very strong addition to the team," said Gene
Walther, Chief Executive Officer of Vortex Biosciences. "Her
extensive experience and strategic vision will be a significant
contribution to the company."
"I am excited to be joining Vortex Biosciences at this time when
the company is moving towards commercialization of their lead
asset," Deborah Neff commented. "I look forward to working with the
team during this dynamic time."
The VTX-1 system, with a planned commercial launch in the first
quarter of 2017, is a fully automated benchtop system for capturing
intact circulating tumor cells (CTCs) directly from whole blood
samples without any preprocessing steps. The proprietary Vortex
technology uses microvortices to stably capture the larger, more
deformable CTCs, while white and red blood cells flow past.
Captured CTCs are then released in a 300 uL volume in a container
of the user's choice. Representative of cancer status in the
patient, CTCs, shed by tumors, can potentially reveal disease
recurrence or disease progression earlier than imaging and more
reliably compared with standard biomarkers.
- Ends -
For more information, please contact:
NetScientific Tel: +44 (0)20 3514
François R. Martelet, 1800
M.D., CEO
Ian Postlethwaite, CFO
Stifel Nicolaus Europe Limited Tel: +44 (0) 20 7710
(NOMAD and broker) 7600
Jonathan Senior / David
Arch / Ben Maddison
Consilium Strategic Communications Tel: +44 (0)20 3709
Mary-Jane Elliott / Chris 5700
Gardner / Jessica Hodgson netscientific@consilium-comms.com
/ Chris Welsh / Laura Thornton
About NetScientific Plc
NetScientific is a transatlantic healthcare IP commercialisation
group focused on improving the health and well-being of people with
chronic diseases.
For more information, please visit the website at
www.netscientific.net.
About Vortex Biosciences
Vortex Biosciences is a cancer research and diagnostics company
that integrates cancer biology, microfluidic engineering and
informatics to develop tools for isolating and characterizing
circulating tumor cells. The Vortex VTX-1 instrument harvests
intact circulating tumor cells from whole blood samples for use in
downstream research and clinical applications such as patient
stratification in clinical trials, monitoring disease progression
and drug treatment effectiveness. With a mission to enable
non-invasive diagnosis of cancer and real-time monitoring
throughout a patient's treatment, Vortex is at the forefront of
accelerating cancer research and improving patient outcomes. Vortex
is a core subsidiary of NetScientific plc, a transatlantic
healthcare technology group with an investment strategy focused on
sourcing, funding and commercializing technologies that
significantly improve the health and well-being of people with
chronic diseases. For more information, visit
www.vortexbiosciences.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAZMMZGMVFGVZM
(END) Dow Jones Newswires
October 26, 2016 07:30 ET (11:30 GMT)
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024